文献类型：期刊文献

英文题名：Nitroxide radical conjugated ovalbumin theranostic nanosystem for enhanced dendritic cell-based immunotherapy and T1-magnetic resonance imaging

作者：Hou, Yike[1,2];Kong, Fei[1,2];Tang, Zhe[1,2,3];Zhang, Rui[1,2];Li, Dan[1,2];Ge, Jian[4];Yu, Zhangsen[5];Wahab, Abdul[1,2];Zhang, Yunyang[1,2];Iqbal, M. Zubair[1,2];Kong, Xiangdong[1,2]

机构：[1]Zhejiang Sci Tech Univ, Inst Smart Biomed Mat, Sch Mat Sci & Engn, Hangzhou 310018, Peoples R China;[2]Zhejiang Sci Tech Univ, Zhejiang Mauritius Joint Res Ctr Biomat & Tissue E, Hangzhou 310018, Peoples R China;[3]South China Univ Technol, South China Adv Inst Soft Matter Sci & Technol, Sch Emergent Soft Matter, Guangdong Prov Key Lab Funct & Intelligent Hybrid, Guangzhou 510640, Peoples R China;[4]China Jiliang Univ, Coll Life Sci, 258 XueYuan St,XiaSha Higher Educ Zone, Hangzhou 310018, Zhejiang, Peoples R China;[5]Shaoxing Univ, Sch Med, Med Sci Res Ctr, Lab Nanomed, Shaoxing 312000, Zhejiang, Peoples R China

年份：2024

卷号：373

起止页码：547

外文期刊名：JOURNAL OF CONTROLLED RELEASE

收录：SCI-EXPANDED(收录号：WOS:001282631900001)、、EI(收录号：20243116779816)、Scopus(收录号：2-s2.0-85199709421)、WOS

基金：The authors acknowledge the support of the National Natural Science Foundation of China (52102353, 51902289) , Zhejiang International Science and Technology Cooperation Project (2021C01180, 2024C03019) , the Natural Science Foundation of Zhejiang Province (LQ22E030018, LZ24E020002) and the Cross-Discipline Construction Funding for Biomedical Materials in ZSTU (11113131282202-01 and 11113131282202-02) .

语种：英文

外文关键词：Nitroxide radical; Cancer vaccine; Cancer immunotherapy; Magnetic resonance imaging; Ovalbumin; Contrast agent

外文摘要：Melanoma, known for its aggressive metastatic nature, presents a formidable challenge in cancer treatment, where conventional therapies often fall short. This study introduces a pioneering approach utilizing metal-free nanosystem as tumor vaccines, spotlighting their potential in revolutionizing melanoma treatment. This work employed organic nitroxides, specifically 4-carboxy-TEMPO, in combination with chitosan (CS), to create a novel nanocomposite material- the CS-TEMPO-OVA nanovaccines. This composition not only improves biocompatibility and extends blood circulation time of TEMPO but also marks a significant departure from traditional gadolinium-based contrast agents in MRI technology, addressing safety concerns. CS-TEMPO-OVA nanovaccines demonstrate excellent biocompatibility at both the cellular and organoid level. They effectively stimulate bone marrow-derived dendritic cells (BMDCs), which in turn promote the maturation and activation of T cells. This ultimately leads to a strong production of essential cytokines. These nanovaccines serve a dual purpose as both therapeutic and preventive. By inducing an immune response, activating cytotoxic T cells, and promoting macrophage M1 polarization, they effectively inhibit melanoma growth and enhance survival in mouse models. When combined with alpha PD-1, the CS-TEMPO-OVA nanovaccines significantly bolster the infiltration of cytotoxic T lymphocytes (CTLs) within tumors, sparking a powerful systemic antitumor response that effectively curbs tumor metastasis. The ability of these nanovaccines to control both primary (subcutaneous) and metastatic B16- OVA tumors highlights their remarkable efficacy. Furthermore, the CS-TEMPO-OVA nanovaccine can be administered in vivo via both intravenous and intramuscular routes, both of which effectively enhance the T1 1 contrast of magnetic resonance imaging in tumor tissue. This study offers invaluable insights into the integrated application of these nanovaccines in both clinical diagnostics and treatment, marking a significant stride in cancer research and patient care.